View in EDS HTML Full Text PDF Full Text

Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024.

Saved in:
Bibliographic Details
Title: Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024.
Authors: Zhou S; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Lei L; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Jiang L; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Fu C; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Huang J; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Zhang K; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Wen Y; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Chen J; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China., Zeng Q; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.
Source: Expert opinion on drug safety [Expert Opin Drug Saf] 2026 May; Vol. 25 (5), pp. 981-986. Date of Electronic Publication: 2024 Dec 25.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101163027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-764X (Electronic) Linking ISSN: 14740338 NLM ISO Abbreviation: Expert Opin Drug Saf Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39707983
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhou+S%22">Zhou S</searchLink>; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.<br /><searchLink fieldCode="AU" term="%22Lei+L%22">Lei L</searchLink>; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.<br /><searchLink fieldCode="AU" term="%22Jiang+L%22">Jiang L</searchLink>; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.<br /><searchLink fieldCode="AU" term="%22Fu+C%22">Fu C</searchLink>; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.<br /><searchLink fieldCode="AU" term="%22Huang+J%22">Huang J</searchLink>; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.<br /><searchLink fieldCode="AU" term="%22Zhang+K%22">Zhang K</searchLink>; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.<br /><searchLink fieldCode="AU" term="%22Wen+Y%22">Wen Y</searchLink>; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.<br /><searchLink fieldCode="AU" term="%22Chen+J%22">Chen J</searchLink>; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.<br /><searchLink fieldCode="AU" term="%22Zeng+Q%22">Zeng Q</searchLink>; Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101163027%22">Expert opinion on drug safety</searchLink> [Expert Opin Drug Saf] 2026 May; Vol. 25 (5), pp. 981-986. <i>Date of Electronic Publication: </i>2024 Dec 25.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101163027 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-764X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214740338%22">14740338 </searchLink><i>NLM ISO Abbreviation: </i>Expert Opin Drug Saf <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39707983
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/14740338.2024.2446432
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 981
    Titles:
      – TitleFull: Adverse event of ruxolitinib cream: a real-world analysis based on FDA Adverse Event Reporting System from 2021 to 2024.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhou S
      – PersonEntity:
          Name:
            NameFull: Lei L
      – PersonEntity:
          Name:
            NameFull: Jiang L
      – PersonEntity:
          Name:
            NameFull: Fu C
      – PersonEntity:
          Name:
            NameFull: Huang J
      – PersonEntity:
          Name:
            NameFull: Zhang K
      – PersonEntity:
          Name:
            NameFull: Wen Y
      – PersonEntity:
          Name:
            NameFull: Chen J
      – PersonEntity:
          Name:
            NameFull: Zeng Q
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2026 May
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1744-764X
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 5
          Titles:
            – TitleFull: Expert opinion on drug safety
              Type: main
ResultId 1